Skip to content

Management of Symptomatic Uterine Fibroids in Pregnancy by Laparotomic Myomectomy: a Prospective Cohort Study

Management of Symptomatic Uterine Fibroids in Pregnancy by Laparotomic Myomectomy: a Prospective Cohort Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06009562
Acronym
LPTM-UFs-P
Enrollment
28
Registered
2023-08-24
Start date
2023-08-19
Completion date
2024-01-01
Last updated
2023-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy Related, Uterine Fibroid

Keywords

Uterine fibroids, Pregnancy, myomectomy, fetal outcomes

Brief summary

The frequency of women presenting with a combination of uterine fibroids and pregnancy is in-creasing nowadays. Uterine fibroids in pregnancy are an unfavorable condition in themselves and being reactive to hormonal stimuli, tending to grow, can generate symptoms of different lev-els of severity. Obstetrics and gynecologists are increasingly faced with the problem of clarifying the management tactics of pregnant patients with symptomatic fibroids, who may see their preg-nancy put at risk by these masses.

Interventions

PROCEDURELaparotomic myomectomy during pregnancy

Surgical removal of symptomatic uterine fibroids in pregnancy by laparotomic access

Sponsors

University of Palermo
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* The large and giant size of UFs, which prevent the proper continuation of pregnancy and/or occupy the entire small and large pelvis, as well as invade and/or occupy the abdominal cavity. * Circulatory disorders, evidenced by necrosis of the UFs. * Atypical localization of UFs (cervical, isthmic, intraligamentary, etc.), which caused pelvic organ dysfunction (dysuric phenomena, tenesmus, impediment to the act of defecation, pelvic pain).

Exclusion criteria

* Refusal of LPTM by the patient. * Absence of urgent indication for LPTM during pregnancy.

Design outcomes

Primary

MeasureTime frameDescription
continuation of pregnancy5 monthsPregnancy continuation after surgery.

Secondary

MeasureTime frameDescription
Fetal outcome5 monthsAssessed by APGAR 1 and 5 min, birth weight, and fetal conformation.

Countries

Russia

Contacts

Primary ContactAndrea Etrusco, M.D.
etruscoandrea@gmail.com3881614022

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026